<DOC>
	<DOCNO>NCT02934971</DOCNO>
	<brief_summary>The present project develop automated machine learn approach use multi-modality data ( imaging , laboratory , electrocardiography questionnaire ) increase understand prediction arise heart failure patient schedule cardio-toxic chemotherapy . This algorithmus develop technical cooperation partner Technion , institut biomedical engineering Haifa , Israel .</brief_summary>
	<brief_title>Optimized Multi-modality Machine Learning Approach During Cardio-toxic Chemotherapy Predict Arising Heart Failure</brief_title>
	<detailed_description>The present project develop automated machine learn approach use multi-modality data ( imaging , laboratory , electrocardiography questionnaire ) increase understand prediction arise heart failure patient schedule cardio-toxic chemotherapy . This algorithmus develop technical cooperation partner Prof. Adam lead Technion , institut biomedical engineering . Specific aim : 1 . To collect achievable data patient schedule cardiotoxic chemotherapy baseline , 6 month end therapy - regard imaging ( MRI , echocardiography conventional strain parameter ) , electrocardiography , biomedical marker ( define function liver , kidney , heart hematopoietic bone marrow ) , clinical parameter quality life questionnaire : 2 . To optimize evaluate robust machine learn approach integrate ass data detect early myocardial damage identify optimal parameter ( single combination ) prediction subclinical leave ventricular ( LV ) dysfunction ( stage 1 current study ) . 3 . To perform clinical study ( stage 2 current study ) chemotherapy patient , identify subclinical LV dysfunction , use guide cardioprotective therapy use new machine learn approach comparison actual standard procedure use echocardiographic leave ventricular ejection fraction ( LVEF ) . The purpose study evaluate optimize machine learn approach combine integrate data different image modality laboratory , electrocardiography questionnaire information define value parameter patient management , identification subclinical LV dysfunction , use guide cardioprotective therapy comparison standard approach use conventional echocardiographic parameter . MRI , conventional echocardiographic parameter echocardiographic myocardial deformation image employ different modality approach obtain insight myocardial tissue deformation . We hypothesize new optimize automate algorithm use modality integrate laboratory , electrocardiography questionnaire information improve detection early LV dysfunction , bring new insight potential response chemo patient cardiotoxic therapy . We expect algorithm lead use adjunctive therapy limit development LV dysfunction , interruption chemotherapy development heart failure follow-up thus reduce morbidity cost .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Patients Patients scheduled chemotherapy increase risk cardiotoxicity ( regard 200 Chemo patient stage 1 study 70 Chemo patient stage 2 study ) : use anthracycline trastuzumab ( Herceptin ) breastcancer HER2 mutation OR tyrosine kinase inhibitor ( eg sunitinib ) OR cumulative anthracycline dose &gt; 450g/m2 doxorubicin , equivalent anthracycline cumulative dose ( eg epirubicine &gt; 900g/m2 ) OR increase risk heart failure ( HF ) ( age &gt; 65y , type 2 diabetes mellitus , hypertension , previous cardiac injury eg . myocardial infarction ) 2 . Female age &gt; 18 year 3 . Written inform consent prior study participation 4 . The subject willing able follow procedure outline protocol The department gynecology RWTH University hospital inform principal investigator patient . 1 . Valvular stenosis regurgitation &gt; moderate severity 2 . History previous heart failure ( baseline New York Heart Association NYHA &gt; 2 ) 3 . Inability acquire interpretable image ( identify baseline echo ) 4 . Contraindication perform MRI 5 . Oncologic ( ) life expectancy &lt; 12 month 6 . Pregnant lactating female 7 . Patient committed institution legal regulatory order 8 . Participation parallel interventional clinical trial 9 . The subject receive investigational drug within 30 day prior inclusion study 10 . Relevant renal insufficiency</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>